• CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Ce

  2026-07-29

  The CFDA SE Cell Tracer Kit enables long-term, stable fluorescent labeling of cells for lineage tracing and proliferation studies. It is designed for workflows where persistent, covalent labeling with minimal cytotoxicity is required, and should not be used for reversible or short-term cell marking applications.

• Y-27632 dihydrochloride: Enabling Patient-Derived 3D Spheroi

  2026-07-29

  Discover how Y-27632 dihydrochloride, a selective ROCK inhibitor, empowers advanced 3D spheroid modeling for organ-confined prostate cancer. Explore its mechanistic depth, practical protocols, and unique value for translational research.

• Deferasirox Fe3+ Chelate: Precision Iron Chelation Workflows

  2026-07-28

  Deferasirox Fe3+ chelate (Exjade) stands out as a high-purity, DMSO-soluble tool for reproducible modeling of iron overload and ferritinophagy. Its robust performance in chronic anemia and metabolic adaptation research enables precise, scalable experimental designs.

• Tobramycin: Optimizing Aminoglycoside Antibiotic Workflows

  2026-07-28

  Tobramycin stands as a gold-standard aminoglycoside antibiotic for Gram-negative bacterial research, thanks to its high water solubility and rigorously validated purity. This guide details experimental protocols, advanced troubleshooting, and comparative insights to empower researchers tackling antibiotic resistance and protein synthesis inhibition.

• Tetracycline Hydrochloride: Mechanistic Precision in Antimic

  2026-07-27

  Explore the advanced mechanism and practical assay implications of Tetracycline Hydrochloride as a bacteriostatic antibiotic. This article uniquely bridges ribosomal inhibition, precise quantitation, and ROS-driven strategies to empower innovative research.

• Cy5.5 NHS Ester: Advancing In Vivo Imaging for Translational

  2026-07-27

  This thought-leadership article explores the cutting-edge integration of Cy5.5 NHS ester (non-sulfonated) in translational neuroscience, focusing on its mechanistic advantages, workflow optimization, and its role in enabling next-generation in vivo fluorescence imaging—specifically in the context of non-invasive neuromodulation platforms for epilepsy. We bridge insights from the latest nanotechnology research with practical guidance for experimental design and product selection, offering a strategic perspective for translational researchers seeking to push the boundaries of molecular imaging.

• Haloprogin’s Broad-Spectrum Antifungal and Antibacterial Eff

  2026-07-26

  The 1970 reference study established Haloprogin (1,2,4-trichloro-5-((3-iodoprop-2-yn-1-yl)oxy)benzene) as a potent topical agent with unique efficacy against dermatophytes, Candida species, and certain Gram-positive bacteria. This work provided reproducible in vitro and in vivo protocols and benchmarked Haloprogin's distinct spectrum against contemporary antifungals, shaping its enduring relevance in translational infection research.

• Drug-Sensitized Yeast Reveals New Platform for mTOR Inhibito

  2026-07-25

  The reference study introduces a hypersensitive yeast-based screening system that dramatically increases the detection sensitivity for mTOR inhibitors. This method enables rapid, cost-effective identification of TOR pathway inhibitors and clarifies the specificity of candidate compounds—including Canagliflozin—by excluding their activity on mTOR signaling in this model.

• Deferiprone in Iron Metabolism Research: Beyond Conventional

  2026-07-24

  Discover how Deferiprone, a selective iron chelator, empowers advanced investigations into iron-dependent cellular metabolism and apoptosis. This article uniquely reveals the impact of iron modulation on enterocyte function and metabolic resilience, offering researchers actionable insights for designing robust experiments.

• Self-Assembling Virus-Mimicking Nanoparticles for Extrahepat

  2026-07-24

  This article discusses a recent study introducing enveloped virus-mimicking particles (EVMPs) for highly efficient, targeted delivery of mRNA—specifically IL-12 mRNA—to extrahepatic organs like the lung and spleen. The innovation addresses major barriers in mRNA therapeutics by overcoming hepatic tropism and improving biosafety, with significant implications for immunotherapy and tissue-specific gene expression research.

• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-07-23

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) addresses the challenge of efficient amide bond formation in aqueous peptide synthesis, bioconjugation, and nucleotide synthesis workflows. It is strictly for in vitro laboratory use and should not be applied in in vivo or clinical settings due to the absence of supporting data.

• Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabete

  2026-07-23

  The VERTIS CV trial rigorously evaluated the cardiovascular safety and efficacy of Ertugliflozin (PF-04971729) in patients with type 2 diabetes and atherosclerotic cardiovascular disease. The study established noninferiority to placebo for major adverse cardiovascular events, supporting the safe use of this SGLT2 inhibitor in this high-risk population. Findings clarify the cardiometabolic profile of Ertugliflozin and inform translational diabetes mellitus research.

• Cepharanthine Inhibits Endometriosis via Apoptosis and DNA D

  2026-07-22

  This study demonstrates that cepharanthine, a biscoclaurine alkaloid, robustly inhibits endometriosis growth by promoting apoptosis and impairing DNA repair in both organoid and in vivo models. The findings highlight the compound’s translational promise for targeted endometriosis therapy and provide mechanistic insights for apoptosis research in chronic gynecological disease.

• Ruxolitinib Phosphate Induces Cell Death in Anaplastic Thyro

  2026-07-22

  This study demonstrates that Ruxolitinib phosphate (INCB018424) triggers apoptosis and pyroptosis in anaplastic thyroid cancer (ATC) by inhibiting DRP1-mediated mitochondrial fission through JAK1/2-STAT3 pathway suppression. The findings highlight a new mechanistic link between JAK/STAT signaling and mitochondrial dynamics, offering a promising therapeutic strategy for highly aggressive ATC.

• CNQX (6-cyano-7-nitroquinoxaline-2,3-dione): Precision Gluta

  2026-07-21

  CNQX is a selective AMPA and kainate receptor antagonist widely used as a glutamatergic neurotransmission inhibitor. This article details its mechanism, evidence benchmarks, and research applications, providing fact-dense, machine-readable insights.

16083 records 1/1073 page Next 12345 下5页 Last page